Bavarian Nordic Announces First Subject Dosed with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bavarian Nordic Announces First Subject Dosed with MVA-BN(r) Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines
  • First human trial investigating MVA-BN® Filo as an Ebola vaccine
  • MVA-BN Filo is being investigated as a booster in an ongoing Phase study 1 of the cAd3-EBO Z vaccine being developed by GSK and the U.S. National Institutes of Health (NIH)

KVISTGAARD, Denmark, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the first subject has been dosed with MVA-BN Filo in a Phase 1 safety and immunogenicity trial, evaluating a heterologous prime-boost regimen of Ebola candidate vaccines. The trial, sponsored by the University of Oxford, is assessing the monovalent cAd3-EBO Z vaccine co-developed by GSK and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and Bavarian Nordic's multivalent MVA-¬BN Filo vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.

Recent preclinical research has shown that by employing an MVA-based booster dose, the vaccine may offer a more robust and durable immune response. The investigators hope to be able to replicate these findings in clinical studies and have therefore chosen to include Bavarian Nordic's MVA-BN Filo vaccine in the study for a heterologous boost.

The study is enrolling 60 healthy adults in three cohorts receiving different doses of the cAd3-EBO Z vaccine. Half of the subjects in each cohort will furthermore receive a booster dose of the MVA-BN Filo vaccine. Primary objective is the assessment of safety and tolerability; secondary objective is the assessment of cellular and humoral immune responses. Preliminary results from the study are anticipated in the first half of 2015. More information on the trial can be found at http://clinicaltrials.gov/ct2/show/NCT02240875 .

Both the cAd3-EBO Z vaccine and the MVA-BN Filo vaccine have been developed in collaboration with NIAID. In partnership with Bavarian Nordic and Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, NIAID furthermore investigated a prime-boost regimen of Bavarian Nordic's MVA-BN Filo and Janssen's AdVac® technology. Based on promising preclinical results, Bavarian Nordic and Janssen recently entered into a collaboration to develop and manufacture large quantities of this vaccine regimen, which is planned to enter clinical trials shortly.

"In support of the various clinical trials currently underway to fast-track the development of urgently needed vaccines against Ebola, we are pleased that these studies may confirm the role of a heterologous prime boost regimen incorporating the MVA-BN vaccine platform technology," said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. "We are also making progress in our collaboration with Janssen as part of their commitment to accelerate and expand the production of its Ebola vaccine regimen. Manufacturing of our MVA-BN Filo vaccine is well underway and the first trial in humans of this prime-boost vaccine regimen will soon open for enrollment."

Contacts
Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.  For more information, visit www.bavarian-nordic.com .

About MVA-BN®
MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic. MVA-BN is a robust and adaptable platform suitable for addressing a wide variety of infectious diseases, including biological threats.

In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU and Canada) essential to protecting the immune-compromised population, Bavarian Nordic has conducted more than a dozen preclinical and clinical studies of recombinant MVA-BN-based vaccines.  More than 7,500 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

201432uk http://hugin.info/100065/R/1877031/661607.pdf

HUG#1877031

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 26

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 183

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 123

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 31

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading

Top 5 Most Recently Viewed Articles

Desreta Jackson's New Show: A Journey of Healing and Legacy

Updated Category News Views 551

Desreta Jackson Unveils Groundbreaking Show This Fall Desreta Jackson, who captivated audiences through her memorable role as young Celie in Steven Spielberg's acclaimed film The Color Purple, is set to make her return to the limelight with the launch of The Desreta Jackson Show this fall. Produced by Desicon Pictures, the show seeks to ignite meaningful conversations...

Continue Reading
Clarios Unveils Ambitious Initiative to Transform U.S. Manufacturing

Updated Category News Views 354

Clarios Set to Revolutionize U.S. Manufacturing Landscape Clarios is embarking on an exciting journey to bolster American manufacturing, with plans to establish a cutting-edge technology campus focusing on advanced supercapacitor systems production. This initiative is part of a comprehensive $6 billion investment strategy aimed at strengthening domestic supply chains....

Continue Reading
Franchise Equity Partners Expands with Strategic Valvoline Deal

Updated Category News Views 274

Franchise Equity Partners Forms Strategic Partnership with Valvoline Franchise Equity Partners (FEP) is thrilled to announce a new strategic partnership with Valvoline Inc. This collaboration marks a significant milestone as FEP plans to acquire 38 Valvoline company-owned stores. The stores, located in various regions of Texas, will be transitioning to a newly established...

Continue Reading
New Found Gold Announces Successful Financing Round Closing

Updated Category News Views 183

Recent Financing Success of New Found Gold New Found Gold Corp. (TSXV: NFG) (NYSE-A: NFGC) is excited to share the successful closing of its second and final tranche in the bought deal financing, securing a remarkable C$63 million to advance its projects. This milestone marks a significant achievement for the Company, facilitating crucial developments in the exploration...

Continue Reading
Joby Aviation Surpasses Expectations in Q3 Financials

Updated Category News Views 194

Joby Aviation's Remarkable Growth in Q3 Joby Aviation, Inc. (NYSE: JOBY) has recently experienced a substantial surge in stock value, reflecting investor confidence following the release of its third-quarter earnings report. This report highlighted significant movements, particularly as it beat estimates on revenue, even though it faced a mixed assessment regarding its...

Continue Reading